• 24 - 26 February, 2021
  • INTEX Osaka, Japan


TOP > Conference

The program for 2021 is to be released around mid Nov.

Conference Program (2020)

Bilingual Sessions (English/Japanese)

Learn from the Industry Leaders!

The program covers hot topics such as  IoT/AI, Cell Therapy, GMP/GDP etc. Apply now for FREE sessions! (Pre-registration Required)

Keynote Session

[IPK-K] Leadership in the Time of Drastic Change -- How to Foster Innovation

Feb. 26 (Wed) 10:30 - 11:30

* Please note that the time has been changed to 10:30-11:30. [As of January 14th, 2020]

Hope and Responsibility for the Next Generation -The Future of Healthcare-

Yoshihiko Hatanaka
Representative Director Chairman of the Board,
Astellas Pharma Inc.

Healthcare needs are drastically changing with the shifting social structure due to aging. Astellas strives to create medical solutions that provide value to society through new technology and digital innovation and by further promoting new ideas and external collaboration.

Special Sessions

[IPK-S6] AI/Deep Learning Brings Innovation to Next-generation Pharma Factory

Feb. 28 (Fri) 10:30 - 12:00

Introduction Example of Artificial Intelligence at Packaging Line for Automatic Line Clearance

Masahiro Kondo
Pharmaceutical Technology, Hikari Plant, Global Manufacturing & Supply Japan,

Takeda Pharmaceutical Co., Ltd.

Takeda is driving innovation applying the latest digital technologies to our manufacturing sites/GEMBA. This time, we successfully developed a new inspection system utilizing artificial intelligence(AI) in collaboration with our vendor and we have started operation on a commercial packaging line as an "automatic line clearance check system". We will introduce this case with our story of development as an example.

Deep Learning for Visual Inspection - Implementation in Automated Inspection Machine under Production Conditions

Jose Maria Zanardi Ocampo
Senior Manager,
Engineering Vision Technology,

Syntegon Technology K.K.

AI is now making its way into the visual inspection of injectable drugs, especially the products difficult to inspect. Utilizing AI algorithm in the image processing will enable automated inspection machines to achieve a desired outcome ‐ higher true detection rate as well as the lower false rejection rate. This lecture will introduce our pilot project of Deep Learning application, including solutions to the challenge of validation.

[IPK-S7] Chinese Pharma Regulatory -- Trends and Tips

Feb. 28 (Fri) 13:00 - 13:50

Regulatory of Pharmaceutical Excipients in China

Jiasheng Tu
Professor of Pharmaceutics,

China Pharmaceutical University

*Dr. Jiasheng Tu will deliver a speech in Chinese.

The seminar has been cancelled. (As of Feb. 26)

Since 2016, China DMF and final product‐associated review system has been implemented for pharmaceutical excipients and packaging materials. China Pharmacopoeia 2020 will be published soon and  have 40 new excipient monographs and 120 revised excipient monographs published. About 30 general chapters for excipients and packaging materials will be implemented.

Key Consideration and Trend for Regulation in China

Yuko Kikuchi
Senior Director,

Eisai Co., Ltd.

China is a very attractive country for Pharmaceutical industries also. However, key consideration for regulatory information and information of current actual operation for drastic current regulatory change is very limited. Speaker will make presentation for key consideration of regulatory information, impact after joining ICH and what you need to know about China today.

Special Session of Regenerative Medicine Expo OSAKA

(Co-held Show)

[RM-S2] Lowering Manufacturing Cost of Regenerative Medicine Products & Cellular Medicine

Feb. 26 (Wed) 13:00 - 14:30

Reducing Cost of Goods for Cell Therapy Manufacturing

Kim Raineri
Vice President of Operations,

Nikon CeLL innovation Co., Ltd.

This speech will provide an overview of the current factors impacting cost of goods for cell based products and review areas for improvement and further development of the manufacturing process and environment that can lead to lower cost of goods.

Key Considerations for the Commercialization of Viral Vectors

Patrick D. Robertson
Director of Technical Sales Operations,
Viral Vector Services, Pharma Services,

Thermo Fisher Scientific

A pragmatic and robust CMC strategy is critical to ensure an efficient path towards commercialization for gene therapy products. This includes considerations for production platform, material needs, product quality, supply chain, timelines, etc. and how all these factors impact process development and manufacturing.

*Honorifics omitted. Please note that recording and photography is strictly prohibited. Speakers and programs are subject to change.
Textbooks of some presentations might not be available. For inquiry regarding conference, please contact visitor-eng.ipj-o@reedexpo.co.jp
Bilingual sessions are free for only those visiting from outside of Japan and registered.

Check 90* more sessions from here!

Available only in Japansese. (Pre-registration Required) *The number includes concurrent conference.

Exhibitors' Presentation

Exhibitors will give presentations about the latest products/technologies.

Please go to the venue (inside exhibition halls) directly.
Please note that some presentations might be given only in Japanese.